Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Menorrhagia 3Leiomyoma 3Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

relugolix 8ulipristal acetate 7telapristone acetate 7estradiol, norethindrone drug combination 7vilaprisan 6asoprisnil 6Estradiol 5linzagolix 4elagolix 4Norethindrone Acetate 3Leuprolide 3Sugars 2Progestins 2epigallocatechin gallate 1Uterine Myomectomy 1Uterine Artery Embolization 1Tranexamic Acid 1Tea 1Standard of Care 1Sodium Chloride 1Saline Solution 1Misoprostol 1Mifepristone 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Laparoscopy 1Iron 1Hysterectomy 1Goserelin 1Gonadotropin-Releasing Hormone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Leiomyoma × Norethindrone Acetate × Clear all
NCT03271489 2025-07-22

Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

AbbVie

Phase 3 Completed
478 enrolled 9 charts

Leiomyoma, Menorrhagia

NCT02691494 2021-07-13

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)

AbbVie

Phase 3 Completed
378 enrolled 16 charts

Leiomyoma, Menorrhagia

NCT02654054 2020-06-29

Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

AbbVie

Phase 3 Completed
413 enrolled 16 charts

Leiomyoma, Menorrhagia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡